Bayer receives approval in China for Stivarga ® (regorafenib) for the second-line systemic Treatment of liver cancer (for specialized target groups only)

Approval based on data from the Phase III RESORCE study where Stivarga ® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib)
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news